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Abstract
Purpose—Our objectives were to determine performance of coded hyperkalemia diagnosis at
identifying 1) clinically-evident hyperkalemia and 2) serum potassium ≥ 6 mmol/liter.
Methods—This retrospective observational study included 8,722 patients with diabetes within an
integrated healthcare system who newly-initiated an angiotensin converting enzyme inhibitor,
angiotensin receptor blocker, or spironolactone. The primary outcome was first hyperkalemia-
associated event (hospitalization, emergency department visit or death within 24 hours of coded
diagnosis and/or potassium ≥ 6 mmol/liter) during the first year of therapy. Medical records were
reviewed.
Results—Among a random sample of 99 patients not coded as having hyperkalemia, none had
hyperkalemia upon record review. Among all 64 patients identified as having hyperkalemia, all
had hospitalization or emergency department visit associated with coded diagnosis or elevated
potassium. Of 55 with coded diagnosis, 42 (PPV 76%) had clinically-evident hyperkalemia; 32
(PPV 58%) had potassium ≥ 6. Of 9 identified using only potassium ≥ 6, 7 (PPV 78%) had
clinically-evident hyperkalemia.
Conclusions—Nearly one-fourth of patients with coded diagnosis do not have clinically-evident
hyperkalemia and nearly one-half do not have potassium ≥ 6. Because both false positives and
negatives occur with coded diagnoses, medical record validation of hyperkalemia-associated
outcomes is necessary.
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• Automated healthcare data can be useful when identifying hyperkalemia-
associated adverse outcomes. Serum potassium laboratory test results provide
incremental value in identifying such outcomes. However, no single automated
data definition of hyperkalemia-associated outcome identifies all patients who
experience clinically-evident hyperkalemia.
• Using coded diagnosis alone without including available serum potassium
concentration information underestimates the number of patients with clinically-
evident outcomes. The combination of coded diagnosis and serum potassium
concentration ≥ 6 mmol/liter also underestimates the number of patients with
clinically-evident outcomes.
• Nearly one-fourth of patients with coded hyperkalemia diagnosis do not have
clinically-evident hyperkalemia and nearly one-half do not have serum
potassium concentration ≥ 6 mmol/Liter.
• Hyperkalemia was not coded as a cause of death. Death certificates were not
useful in identifying patients in whom hyperkalemia may have been a
contributing cause of death.
• Because both false positives and negatives occur with coded hyperkalemia
diagnosis in administrative data, medical record validation of hyperkalemia
outcomes is necessary.
Introduction
Hyperkalemia is an uncommon, potentially fatal consequence of therapies such as
angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB),
potassium-sparing diuretics, potassium supplements, beta-blockers, and nonsteroidal anti-
inflammatory agents.1-7 Serious (> 6 mmol/liter) and severe (> 7 mmol/liter) hyperkalemia
can be life-threatening, but even severe hyperkalemia can sometimes go unrecognized with
few symptoms prior to cardiac arrest.8, 9
The positive predictive value of the International Classification of Diseases, Ninth Revision
(ICD-9) hyperkalemia code has not been evaluated. Further, the proportion of coded
diagnoses associated with elevated potassium concentrations and corresponding signs and
symptoms has not been sufficiently assessed. The performance of the hyperkalemia code is
important because misclassification resulting in under- or overestimation of outcomes would
occur if clinically-evident hyperkalemia was present but not coded or coded but only
incidental to the medical visit. The aims of this study were to determine the performance of
a coded hyperkalemia diagnosis in administrative data at identifying patients with clinically-
evident hyperkalemia and serum potassium ≥ 6 mmol/liter.
Methods
This study was conducted using the patient cohort from one of the three integrated
healthcare delivery systems involved in a large retrospective observational study of serious
hyperkalemia among ambulatory patients with diabetes newly-initiating ACEi, ARB, and or
spironolactone.10-12 The KPCO Institutional Review Board approved this study and waived
the informed consent requirement.
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This study cohort included patients with diabetes without end-stage renal disease (ESRD)
who were Kaiser Permanente Colorado (KPCO) members with pharmacy benefits for at
least 12 months between January 1, 2001 and December 31, 2006. These 8,722 individuals
averaged 61.5 (SD 13.4) years of age and included 4,147 females (47.6%). Most patients
were initially dispensed an ACEi (n = 8,085; ARB n = 447; spironolactone n = 136;
combination n = 54) and remained on the initial therapy for a mean of 227 (SD 139) days.
Patients were censored from the study at the last day of the dispensed days' supply, death,
first hyperkalemia outcome, ESRD diagnosis, disenrollment, or end of the study.
The primary outcome was the first hyperkalemia-associated event, defined as a) potassium
concentration ≥ 6 mmol/liter, b) coded diagnosis of hyperkalemia (ICD9 276.7), or c)
combination of “a” and “b” co-occurring within 24 hours of an inpatient (IP) or emergency
department (ED) claim or death (ICD10 code) within 365 days after initiating therapy. We
previously determined the sensitivity (SE) and specificity (SP) of KPCO administrative data
to be excellent at identifying both drug dispensing and potassium monitoring.13 To ensure
capture of deaths, we accessed disenrollment records, hospital discharge status, the KPCO
mortality database, and death certificates.
To enable calculation of the positive predictive values (PPV) of a hyperkalemia diagnosis in
automated data at identifying patients with 1) clinically-evident hyperkalemia and 2)
potassium > 6, the medical records of all patients identified as meeting the outcome
definition were requested for review. The medical record was considered the gold standard.
To estimate the SE and SP of automated data at identifying hyperkalemia, we assumed that
reviewing records of a random sample of 100 patients identified from automated data as not
having hyperkalemia represented the population. Abstractions were conducted by one
clinical pharmacist (MLS). As a quality check, five percent of abstractions were re-
abstracted by the lead investigator (MAR).
Patients were considered to have clinically-evident hyperkalemia when any of the following
were documented:
• Signs: Complete or other atrioventricular (AV) block, AV dissociation, paroxysmal
ventricular tachycardia, ventricular fibrillation/flutter, cardiac arrest, bradycardia,
other dysrhythmias, insertion of a temporary pacemaker.
• Treatment: Potassium binding resin, intravenous glucose plus insulin, intravenous
calcium, hydration, acute hemodialysis.
• Change in clinical plan: Discontinuation or adjustment in ACEi/ARB/
spironolactone dosage/frequency, change to another ACEi/ARB/spironolactone,
order for additional potassium monitoring, other (e.g., discontinuing potassium
supplement).
We obtained data from pharmacy, diagnosis, laboratory, and other KPCO databases,
ambulatory electronic medical records (EMR), ED or IP medical records, and death
certificates. In analyzing the random sample of patients identified as not experiencing
hyperkalemia, we encountered zero counts. Because zero counts do not necessarily imply no
risk,14 to quantify uncertainty, exact binomial confidence intervals were constructed with
permutations.15 All data checks and analyses were performed with SAS version 9.1 (SAS
Institute Inc., Cary, North Carolina).
Results
Among the 8,722 patients, 71 (0.8%) experienced an IP or ED visit associated with
potassium ≥ 6.0 mmol/L and/or a coded hyperkalemia diagnosis occurring within 24 hours
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of each other (Figure). Ambulatory EMR information was available for all 71 patients and
for the 100 randomly-sampled patients. IP/ED information was not available for six
(Figure), that is, we accessed comprehensive records for 96.5% (165 of 171). During record
review, two patients were identified as prevalent medication users and excluded. The final
number of patients included in analysis was 64 with and 99 without outcome.
Of the 99 patients identified in administrative data as not having a hyperkalemia outcome,
none had hyperkalemia upon record review (Figure, Table). Of the 64 patients identified in
administrative data as having hyperkalemia (Figure), all had an IP/ED visit associated with
hyperkalemia (Table). Overall, 49 of 64 (PPV 77%) had clinical signs of, received treatment
for, and/or had a change in clinical plan associated with hyperkalemia (Table), including 42
of 55 (PPV 76%) with coded diagnosis. Thirty-two of these 55 (PPV 58%) had potassium ≥
6 documented.
When considering the highest potassium at the time the patient experienced hyperkalemia,
all 9 who had an IP/ED visit plus potassium ≥ 6 without coded diagnosis had documented
potassium ≥ 6. Twenty of 41 who had a medical visit and coded diagnosis also had
potassium ≥ 6 documented, but for others in this subgroup, the highest potassium identified
was between 5.5 – 5.9 (12 patients) or ≤ 5.4 (9 patients). Among 14 who met outcome
criteria based on medical visit, coded diagnosis and potassium ≥ 6, when the record was
reviewed, 12 had documented potassium ≥ 6, while two had potassium between 5.5 and 5.9.
No patient had a coded diagnosis of hyperkalemia-associated death. However, five whose
charts were reviewed died at the time of the hyperkalemia, as did one whose chart was
unavailable. In three, the visit note stated that hyperkalemia likely contributed to death (e.g.,
“cardiac arrest, likely due to hyperkalemia”). Hyperkalemia was not mentioned on the death
certificate of any patient.
Discussion
Our study demonstrates that no single automated data definition of hyperkalemia-associated
outcome identifies all patients who experience clinically-evident hyperkalemia. Using coded
diagnosis without including potassium concentration information underestimates the number
of patients with clinically-evident outcomes: Seven of 49 symptomatic patients would have
been misclassified if we had not incorporated potassium concentration data. Nine patients
who had potassium ≥ 6 did not have a coded diagnosis; seven of these had clinically-evident
hyperkalemia. Conversely, although one might think the combination of coded diagnosis
plus potassium ≥ 6 would optimize identifying clinically-evident hyperkalemia, requiring
the combination would have only identified 12 of 49 symptomatic patients.
Our results also demonstrate that the PPV of the diagnosis code is very good (PPV 77%) at
identifying clinically-evident hyperkalemia, but performs less well at identifying patients
with potassium ≥ 6 (PPV 58%). Finally, we found that the hyperkalemia death code and
death certificates were not useful in identifying patients in whom hyperkalemia may have
contributed to death.
Concern about outcomes misclassification was the basis for this study. We found that 15 (of
64) patients identified with hyperkalemia from administrative data did not have clinical
signs or treatment or a change in clinical plan, including 13 (of 55) with coded diagnosis.
Some think that if clinical signs and treatment are lacking, a hyperkalemia diagnosis should
not be coded. However, others think that when potassium is > 5.0, hyperkalemia should be
coded. If we had used the latter value, one patient would have been considered misclassified.
However, we used the stringent requirement of potassium ≥ 6 that resulted in 23 being
considered misclassified.
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This work presents a picture of hyperkalemia among patients with diabetes treated with
ACEi, ARB, or spironolactone in a real-world setting. To determine the performance and
validity of automated data, we abstracted records of all patients identified as having a
hyperkalemia-associated IP/ED visit or death. We applied consistent definitions and
accessed comprehensive databases. The net result is that we present an inclusive clinical and
administrative picture of patients with serious hyperkalemia outcomes.
The project was conducted at one healthcare system; the results may not be fully
generalizable elsewhere. However, treating clinicians within this system are unlikely to
differ substantially from clinicians in other systems in diagnostic acumen, treatment
strategies, or documentation habits. This validation study was limited to outcomes
associated with an IP or ED visit or death and the results cannot be extrapolated to patients
without these types of medical visits. Further, these outcomes were measured among adults
with diabetes and may not be applicable to other populations.
Conclusion
Automated healthcare data can be useful when identifying hyperkalemia-associated adverse
outcomes. Potassium laboratory test results provide incremental value in identifying such
outcomes. Because both false positives and negatives occur with coded hyperkalemia
diagnosis, medical record validation is necessary.
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Figure. Hyperkalemia-Associated Outcomes in Automated Data and Medical Record
Documentation of Hyperkalemia-Associated Clinical Signs, Treatment, and/or Change in
Clinical Plan
* See text for definitions
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